Another Medical Cannabis Clinical Trial Launches in South Africa

Another Medical Cannabis Clinical Trial Launches in South Africa

A clinical trial was recently initiated by South African Cannabis Institute (CRI) partnered with Releaf Cannabis E-Clinics to see how medical cannabis could help treat opioid addiction.

The trial will last for a year to see how cannabis affects chronic pain in patients.according to business techthe results will be provided to “relevant authorities” who can use that information to regulate medical cannabis in the country.

The judgment Dr. Shiksha Gallow, she works with her team to conduct an investigation. “Although the South African Health Products Regulatory Authority (SAHPRA) does not yet have a formal cannabis-containing medicine approved as an analgesic, anecdotal evidence and preliminary studies suggest it could be highly effective in pain management. It shows sex,” Gallow said.

Gallow explained that chronic pain is defined as lasting longer than six months.Treatments for chronic pain include opioids such as morphine, oxycodone, and codeine, which target opioid receptors in patients. block pain messages sent from the body. However, patients develop tolerance over time, so the medication only works for a while before the dosage has to be increased. It’s associated with side effects,” Gallow said. “With the rise of opiate addiction worldwide, with far-reaching consequences ranging from disease to wider social problems such as crime, research is focused on establishing safer alternatives to treating pain. I guess.”

CRI is relief pharmaceuticals To research cannabis and find safer medical options for patients. Willco Janse van Vuuren, managing director of the company, said he was excited to start the study. “and relief pharmaceuticals (proud member Impiro Vest Group), who believe that being healthy is a basic human right. Social, mental and physical health are at the heart of everything we do.we are proud to work together Dr. Shiksha Gallow and the South African Cannabis Institute This groundbreaking study will help you find natural solutions to pain management that are safe and effective. ” LinkedIn’s van Vuuren said:.

While opioid addiction is the leading cause of death, thousandsThere is evidence that medical cannabis can help treat chronic pain without the risk of addiction or overdose. increase. “This study aims to highlight the benefits of cannabis therapeutics. South Africa has the resources, technology and manpower to make it happen, thus setting the standard for medical cannabis in the global market.” We are poised,” Drington said.

In June 2022, the first clinical trial in South Africa will be launched by Labat Africa and its subsidiary Biodata, also collaborating with Gallow. The study, called the “Pharma Ethics Observational Study,” also analyzed how medical cannabis could help replace opioids in chronic pain.The study works with 1,000 patients who have been on prescribed opioids for at least three months and are given cultivar Tallyman and Exodus (Provided by Labat-based Sweetwaters Aquaponics).strain called 9 pound hammer It was grown for this use by Sweetwaters Aquaponics, known for its high percentage of THC and CBG cannabinoids.

As in many places in the United States, researchers in South Africa are also looking at how psilocybin could be used medically. A study was initiated to investigate the

South Africa is slowly developing as a cannabis destination. In July 2022, a town in Johannesburg (located in the north-central part of the country) hosted his three-day cannabis festival.

With two decades of dedicated experience, Nuggs is a seasoned cannabis writer and grower. His journey has been a harmonious blend of nurturing cannabis from seed to harvest and crafting insightful content. A true expert, they've honed strain-specific knowledge, cultivation techniques, and industry insights. His passion shines through enlightening articles and thriving gardens, making them a respected figure in both the growing and writing facets of the cannabis world.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *